The day analysts can finally value a company is often the day it gets cheaper.
Imagine a drug company with no revenue trading at billions. A value investor looks at it and sees nothing: no cash flows, no earnings, nothing to discount. An options trader looks at the same ticker and sees a fat implied volatility surface pricing in the chance of FDA approval. Each is locally correct, and each thinks the other is a fool. Like the blind men and the elephant, each touches a real part of the animal and builds a confident but incomplete picture of it.
Now suppose the drug is approved and the company starts selling it. The business has plainly improved. Why might the stock fall?
Two ways to price one asset
Before approval, the company is less a business than a black box holding a far-out-of-the-money call option. Its value is made up entirely of possibility, and the imagination extrinsic is the entire price. The Black-Scholes model, which treats price movement as a random walk, is built for that kind of asset. A steady cash-flow generator belongs to the value investor instead, who decidedly does not see prices as a random walk.
Neither model sets the price alone. At any given moment the price is more a function of the derivatives market than of the fundamentals. Options market-makers hedge by buying or selling the underlying, which moves the price, which changes the options pricing, which changes the hedging. The price settles where short-term options traders can no longer earn hurdle-clearing alpha by taking a bullish or bearish stance: a Schelling point held in place by active trading. So the stock market runs two pricing engines simultaneously — a fundamentals engine and a derivatives engine — and the price at any moment reflects whichever engine has more active participants.
The transition trap
That answers the drug company’s puzzle. An improving company can actually go down in price when intrinsic value rises slower than imagination extrinsic falls. Approval makes the company legible: multiples that could not be modeled before can now be calculated, and the narrative premium collapses faster than the fundamentals improve. A high PSR reflected possibility, and the move from “unmeasurable possibility” to “measurable business” destroys the premium that justified it.
That gap between two confident but partial views is where the opportunity lives. The moment of maximum opportunity is the transition, when the market is still pricing a stock by one framework while the reality has shifted to the other.
Why doesn’t someone simply force the price back into line? Because value investors are not in control: selling short is too dangerous, and even short sellers mostly hunt for frauds with obvious catalysts. Without a forcing mechanism, the gap can persist indefinitely. The market is not wrong. It is playing a different game.
The limit is that knowing two engines exist does not tell you which one is in charge this quarter, or when the handoff will come, and the transition is exactly when the market itself is most uncertain. Recognizing the regime is a skill, not a formula.
What the picture does change is the quarrel between the two camps. Their models are not rival theories of one reality but descriptions of different regimes that the same asset moves between. A young stock is an options contract, valued by its volatility surface; a mature one is a bond with upside, valued by its cash flows, and the most violent price moves happen at the handoff. The blind men are not wrong about the elephant. They are just touching it at different times in its life.
References:
- Personal framework for reconciling BSM and fundamental analysis
- Ricki Heicklen, Why Investing Feels Like Astrology